MODUL 3 - Applied Research Approaches & Vaccine Development

From the Antigenome of Major Fungal Pathogens to Vaccine Development

Objective 3-1: Extension of the proprietary Antigenome technology using polyclonal antisera against Candida spp, and clinical patient sera (in collaboration with Birgit Willinger; AKH General Hospital Vienna) to identify antigens eliciting immune responses

Objective 3-2: Exploitation of the Antigenome technology at the genome-wide scale, paired with bioinformatics (in collaboration with the Arndt von Haeseler; CIBIV) to define the Antigenome of major fungal pathogens (Candida spp & Aspergillus spp)

Objective 3-3: Exploitation of proteomic approaches (collaboration with Gustav Ammerer; CDL for Proteomics) to identify and confirm high-priority antigens, followed by production of recombinant antigens and the generation of high-affinity monoclonal antibodies

Objective 3-4: Establishment and use of suitable mouse models for validating candidate vaccines identified by the Antigenome technology for possible in vivo protection and cure against systemic fungal diseases